35:271 Patent Infringement
A federal judge overseeing the multidistrict litigation arising from Sanofi-Aventis SA’s prostate drug Uroxatral has held that the patent covering the treatment was valid and infringed by Apotex Inc.’s proposed generic copycat.
A federal judge has ruled that Sanofi-Aventis’ patent covering prostate treatment Uroxatral is valid and infringed by proposed generic versions from Aurobindo Pharma Ltd. and Torrent Pharma Inc.
A federal judge has given Sanofi-Aventis SA a boost in its multidistrict litigation over competitors' attempts to market a generic version of prostate treatment Uroxatral, ruling at trial that the drug proposed by Mylan Pharmaceutical Inc. would in fact infringe Sanofi’s patent.
A federal judge has handed down a claim construction order for one of the patents in Sanofi-Aventis’ multidistrict litigation alleging Mylan Pharmaceuticals Inc. and other generic-drug manufacturers have infringed its technology covering its prostate treatment, Uroxatral.
Sanofi-Aventis has hit Sun Pharmaceutical Industries Ltd. with another patent infringement suit over the drug Uroxatral, alleging that the generics maker infringed another of its patents for the prostate treatment.